$SHPH

Collegium Pharmaceutical, Inc. has announced its acquisition of AZSTARYS, which aims to bolster its portfolio in the ADHD market. This strategic move is expected to enhance Collegium's growth prospects and diversify its product offerings. The acquisition underscores the company's commitment to addressing ADHD treatment needs, positioning them competitively in the pharmaceutical sector. Investors view this acquisition positively, indicating a strong future outlook for Collegium. Overall, this development is seen as a pivotal step towards increased market share in a growing segment.